These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

433 related items for PubMed ID: 9193198

  • 1. The effects of a selective D4 dopamine receptor antagonist (L-745,870) in acutely psychotic inpatients with schizophrenia. D4 Dopamine Antagonist Group.
    Kramer MS, Last B, Getson A, Reines SA.
    Arch Gen Psychiatry; 1997 Jun; 54(6):567-72. PubMed ID: 9193198
    [Abstract] [Full Text] [Related]

  • 2. Quetiapine in patients with schizophrenia. A high- and low-dose double-blind comparison with placebo. Seroquel Study Group.
    Small JG, Hirsch SR, Arvanitis LA, Miller BG, Link CG.
    Arch Gen Psychiatry; 1997 Jun; 54(6):549-57. PubMed ID: 9193196
    [Abstract] [Full Text] [Related]

  • 3. A double-blind, randomized, placebo-controlled study with JNJ-37822681, a novel, highly selective, fast dissociating D₂ receptor antagonist in the treatment of acute exacerbation of schizophrenia.
    Schmidt ME, Kent JM, Daly E, Janssens L, Van Osselaer N, Hüsken G, Anghelescu IG, Van Nueten L.
    Eur Neuropsychopharmacol; 2012 Oct; 22(10):721-33. PubMed ID: 22464973
    [Abstract] [Full Text] [Related]

  • 4. Aripiprazole, an antipsychotic with a novel mechanism of action, and risperidone vs placebo in patients with schizophrenia and schizoaffective disorder.
    Potkin SG, Saha AR, Kujawa MJ, Carson WH, Ali M, Stock E, Stringfellow J, Ingenito G, Marder SR.
    Arch Gen Psychiatry; 2003 Jul; 60(7):681-90. PubMed ID: 12860772
    [Abstract] [Full Text] [Related]

  • 5. Effectiveness of the selective D4 antagonist sonepiprazole in schizophrenia: a placebo-controlled trial.
    Corrigan MH, Gallen CC, Bonura ML, Merchant KM, Sonepiprazole Study Group.
    Biol Psychiatry; 2004 Mar 01; 55(5):445-51. PubMed ID: 15023570
    [Abstract] [Full Text] [Related]

  • 6. Vitamin B6 treatment in acute neuroleptic-induced akathisia: a randomized, double-blind, placebo-controlled study.
    Lerner V, Bergman J, Statsenko N, Miodownik C.
    J Clin Psychiatry; 2004 Nov 01; 65(11):1550-4. PubMed ID: 15554771
    [Abstract] [Full Text] [Related]

  • 7. Adjunctive treatment with a dopamine partial agonist, aripiprazole, for antipsychotic-induced hyperprolactinemia: a placebo-controlled trial.
    Shim JC, Shin JG, Kelly DL, Jung DU, Seo YS, Liu KH, Shon JH, Conley RR.
    Am J Psychiatry; 2007 Sep 01; 164(9):1404-10. PubMed ID: 17728426
    [Abstract] [Full Text] [Related]

  • 8. Frontal fasciculi and psychotic symptoms in antipsychotic-naive patients with schizophrenia before and after 6 weeks of selective dopamine D2/3 receptor blockade.
    Ebdrup BH, Raghava JM, Nielsen MØ, Rostrup E, Glenthøj B.
    J Psychiatry Neurosci; 2016 Mar 01; 41(2):133-41. PubMed ID: 26599135
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Placebo-controlled study of the D4/5-HT2A antagonist fananserin in the treatment of schizophrenia.
    Truffinet P, Tamminga CA, Fabre LF, Meltzer HY, Rivière ME, Papillon-Downey C.
    Am J Psychiatry; 1999 Mar 01; 156(3):419-25. PubMed ID: 10080558
    [Abstract] [Full Text] [Related]

  • 11. Randomized, controlled, double-blind multicenter comparison of the efficacy and tolerability of ziprasidone and olanzapine in acutely ill inpatients with schizophrenia or schizoaffective disorder.
    Simpson GM, Glick ID, Weiden PJ, Romano SJ, Siu CO.
    Am J Psychiatry; 2004 Oct 01; 161(10):1837-47. PubMed ID: 15465981
    [Abstract] [Full Text] [Related]

  • 12. Improvement of negative and positive symptoms in treatment-refractory schizophrenia: a double-blind, randomized, placebo-controlled trial with memantine as add-on therapy to clozapine.
    de Lucena D, Fernandes BS, Berk M, Dodd S, Medeiros DW, Pedrini M, Kunz M, Gomes FA, Giglio LF, Lobato MI, Belmonte-de-Abreu PS, Gama CS.
    J Clin Psychiatry; 2009 Oct 01; 70(10):1416-23. PubMed ID: 19906345
    [Abstract] [Full Text] [Related]

  • 13. Beneficial antipsychotic effects of allopurinol as add-on therapy for schizophrenia: a double blind, randomized and placebo controlled trial.
    Akhondzadeh S, Safarcherati A, Amini H.
    Prog Neuropsychopharmacol Biol Psychiatry; 2005 Feb 01; 29(2):253-9. PubMed ID: 15694232
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Dopamine D4 receptors: a new opportunity for research on schizophrenia.
    Liégeois J, Eyrolles L, Bruhwyler J, Delarge J.
    Curr Med Chem; 1998 Apr 01; 5(2):77-100. PubMed ID: 9481035
    [Abstract] [Full Text] [Related]

  • 16. Olanzapine versus placebo in adolescents with schizophrenia: a 6-week, randomized, double-blind, placebo-controlled trial.
    Kryzhanovskaya L, Schulz SC, McDougle C, Frazier J, Dittmann R, Robertson-Plouch C, Bauer T, Xu W, Wang W, Carlson J, Tohen M.
    J Am Acad Child Adolesc Psychiatry; 2009 Jan 01; 48(1):60-70. PubMed ID: 19057413
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Placebo-controlled evaluation of four novel compounds for the treatment of schizophrenia and schizoaffective disorder.
    Meltzer HY, Arvanitis L, Bauer D, Rein W, Meta-Trial Study Group.
    Am J Psychiatry; 2004 Jun 01; 161(6):975-84. PubMed ID: 15169685
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Control group bias in randomized atypical antipsychotic medication trials for schizophrenia.
    Woods SW, Gueorguieva RV, Baker CB, Makuch RW.
    Arch Gen Psychiatry; 2005 Sep 01; 62(9):961-70. PubMed ID: 16143728
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 22.